News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
286,577 Results
Type
Article (15177)
Company Profile (299)
Press Release (271094)
Multimedia
Podcasts (95)
Webinars (12)
Section
Business (79948)
Career Advice (163)
Deals (13384)
Drug Delivery (44)
Drug Development (50800)
Employer Resources (31)
FDA (5898)
Job Trends (5185)
News (145350)
Policy (10081)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Standard (3)
Academia (936)
Accelerated approval (25)
Adcomms (14)
Allergies (101)
Alliances (21762)
ALS (157)
Alzheimer's disease (1112)
Antibody-drug conjugate (ADC) (354)
Approvals (6154)
Artificial intelligence (336)
Autoimmune disease (218)
Automation (10)
Bankruptcy (105)
Best Places to Work (4561)
BIOSECURE Act (6)
Biosimilars (117)
Biotechnology (230)
Bladder cancer (118)
Brain cancer (57)
Breast cancer (407)
Cancer (3791)
Cardiovascular disease (278)
Career advice (151)
Career pathing (8)
CAR-T (255)
CDC (7)
Celiac Disease (1)
Cell therapy (674)
Cervical cancer (21)
Clinical research (44571)
Collaboration (1395)
Company closure (3)
Compensation (719)
Complete response letters (54)
COVID-19 (1118)
CRISPR (104)
C-suite (719)
Cystic fibrosis (117)
Data (5345)
Denatured (20)
Depression (110)
Dermatology (51)
Diabetes (298)
Diagnostics (1428)
Digital health (16)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (247)
Drug pricing (52)
Drug shortages (6)
Duchenne muscular dystrophy (266)
Earnings (32534)
Editorial (33)
Employer branding (4)
Employer resources (29)
Events (52908)
Executive appointments (679)
FDA (7991)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (14)
Frontotemporal dementia (30)
Funding (1150)
Gene editing (219)
Generative AI (29)
Gene therapy (581)
GLP-1 (557)
Government (1179)
Grass and pollen (3)
Guidances (172)
Healthcare (6658)
HIV (26)
Huntington's disease (50)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (83)
Immunology and inflammation (229)
Immuno-oncology (69)
Indications (121)
Infectious disease (1263)
Inflammatory bowel disease (181)
Inflation Reduction Act (10)
Influenza (54)
Intellectual property (196)
Interviews (18)
IPO (7361)
IRA (13)
Job creations (868)
Job search strategy (130)
JPM (41)
Kidney cancer (9)
Labor market (27)
Layoffs (250)
Leadership (12)
Legal (1405)
Liver cancer (44)
Longevity (23)
Lung cancer (497)
Lymphoma (283)
Machine learning (33)
Management (7)
Manufacturing (480)
MASH (150)
Medical device (2696)
Medtech (2711)
Mergers & acquisitions (6733)
Metabolic disorders (860)
mRNA (147)
Multiple sclerosis (119)
NASH (14)
Neurodegenerative disease (299)
Neuropsychiatric disorders (81)
Neuroscience (2216)
Neurotech (1)
NextGen: Class of 2026 (2036)
Non-profit (876)
Now hiring (38)
Obesity (393)
Opinion (138)
Ovarian cancer (168)
Pain (130)
Pancreatic cancer (206)
Parkinson's disease (280)
Partnered (12)
Patents (372)
Patient recruitment (470)
Peanut (47)
People (27076)
Pharmaceutical (42)
Pharmacy benefit managers (6)
Phase 1 (15789)
Phase 2 (20747)
Phase 3 (13073)
Pipeline (5274)
Policy (103)
Postmarket research (853)
Preclinical (6705)
Press Release (30)
Prostate cancer (183)
Psychedelics (58)
Radiopharmaceuticals (270)
Rare diseases (825)
Real estate (1456)
Recruiting (12)
Regulatory (10420)
Reports (20)
Research institute (981)
Resumes & cover letters (20)
Rett syndrome (32)
RNA editing (25)
RSV (24)
Schizophrenia (144)
Series A (225)
Series B (155)
Service/supplier (1)
Sickle cell disease (89)
Special edition (19)
Spinal muscular atrophy (124)
Sponsored (17)
Startups (2024)
State (1)
Stomach cancer (5)
Supply chain (41)
Tariffs (19)
The Weekly (73)
Vaccines (383)
Venture capital (83)
Weight loss (212)
Women's health (42)
Worklife (2)
Date
Last 7 days (548)
Last 30 days (1820)
Last 365 days (17845)
2026 (6666)
2025 (18102)
2024 (20542)
2023 (22411)
2022 (26822)
2021 (27803)
2020 (23356)
2019 (16224)
2018 (11737)
2017 (13745)
2016 (11839)
2015 (14348)
2014 (10392)
2013 (7485)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (71)
Alaska (2)
Arizona (82)
Arkansas (6)
Asia (18558)
Australia (3182)
California (8188)
Canada (2107)
China (941)
Colorado (294)
Connecticut (307)
Delaware (279)
Europe (39897)
Florida (1046)
Georgia (240)
Hawaii (2)
Idaho (17)
Illinois (478)
India (43)
Indiana (192)
Iowa (8)
Japan (281)
Kansas (82)
Kentucky (11)
Louisiana (12)
Maine (12)
Maryland (850)
Massachusetts (6482)
Michigan (123)
Minnesota (289)
Mississippi (3)
Missouri (35)
Montana (17)
Nebraska (6)
Nevada (44)
New Hampshire (22)
New Jersey (1876)
New Mexico (13)
New York (2031)
North Carolina (954)
North Dakota (6)
Northern California (4122)
Ohio (205)
Oklahoma (11)
Oregon (23)
Pennsylvania (1508)
Puerto Rico (11)
Rhode Island (27)
South America (216)
South Carolina (12)
Southern California (3275)
Tennessee (49)
Texas (1100)
United States (27041)
Utah (113)
Virginia (170)
Washington D.C. (37)
Washington State (673)
West Virginia (1)
Wisconsin (54)
286,577 Results for "remix therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Remix Therapeutics Granted FDA Fast Track Designation for REM-422 for the Treatment of Recurrent, Metastatic or Unresectable Adenoid Cystic Carcinoma
March 19, 2026
·
4 min read
Press Releases
Remix Therapeutics Appoints Mythili Koneru, MD, PhD, as Chief Medical Officer
January 6, 2026
·
3 min read
Press Releases
Remix Therapeutics Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting
April 21, 2026
·
3 min read
Press Releases
Remix Therapeutics to Present at Guggenheim Second Annual Healthcare Innovation Conference
November 4, 2025
·
1 min read
Press Releases
Remix Therapeutics to Present Phase 1 Data of REM-422 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Conference in Late-Breaking Oral Presentation
October 14, 2025
·
3 min read
Press Releases
Remix Therapeutics Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 27, 2025
·
4 min read
Business
Remix Therapeutics™ Appoints Maria Koehler, M.D., Ph.D., as an Independent Board Director
Remix Therapeutics today announced the appointment of Maria Koehler, M.D., Ph.D., as an independent director to Remix’s Board of Directors.
June 18, 2024
·
2 min read
Press Releases
Remix Therapeutics Appoints Linda C. Bain to Board of Directors
April 16, 2025
·
2 min read
Genetown
Remix Therapeutics to Participate in Upcoming Investor Conferences
Remix Therapeutics today announced that management will participate in several upcoming investor conferences.
February 7, 2024
·
1 min read
Genetown
Remix Therapeutics Announces Participation in Jefferies 2024 Healthcare Conference
Remix Therapeutics announced that its management team will host one-on-one meetings with investors at the Jefferies Healthcare Conference taking place on Tuesday, June 4, 2024 in New York City.
May 28, 2024
·
1 min read
1 of 28,658
Next
